The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

The US Food and Drug Administration (FDA) has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

NYU Langone Health in New York City reportedly cancelled the appointments of two transgender children scheduled to receive ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Amanda Salindong, associate director of channel & distribution at Alnylam Pharmaceuticals, explains the premise ...